NICE rejection of abiraterone before chemotherapy in advanced prostate cancer

Janssen statement in response to the NICE Final Appraisal Determination (FAD) on the use of Zytiga® (abiraterone acetate) prior to chemotherapyJanssen is extremely disappointed with the...